167 related articles for article (PubMed ID: 37822244)
1. Tissue factor pathway inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer.
Englisch C; Moik F; Thaler J; Koder S; Mackman N; Preusser M; Pabinger I; Ay C
Haematologica; 2024 Apr; 109(4):1128-1136. PubMed ID: 37822244
[TBL] [Abstract][Full Text] [Related]
2. Total tissue factor pathway inhibitor and venous thrombosis. The Longitudinal Investigation of Thromboembolism Etiology.
Zakai NA; Lutsey PL; Folsom AR; Heckbert SR; Cushman M
Thromb Haemost; 2010 Aug; 104(2):207-12. PubMed ID: 20431849
[TBL] [Abstract][Full Text] [Related]
3. Hemostatic Biomarkers and Venous Thromboembolism Are Associated With Mortality and Response to Chemotherapy in Patients With Pancreatic Cancer.
Moik F; Prager G; Thaler J; Posch F; Wiedemann S; Schramm T; Englisch C; Mackman N; Pabinger I; Ay C
Arterioscler Thromb Vasc Biol; 2021 Nov; 41(11):2837-2847. PubMed ID: 34470475
[TBL] [Abstract][Full Text] [Related]
4. Growth differentiation factor-15 and prediction of cancer-associated thrombosis and mortality: a prospective cohort study.
Nopp S; Moik F; Kraler S; Englisch C; Preusser M; von Eckardstein A; Pabinger I; Lüscher TF; Ay C
J Thromb Haemost; 2023 Sep; 21(9):2461-2472. PubMed ID: 37192696
[TBL] [Abstract][Full Text] [Related]
5. Single nucleotide polymorphisms in an intergenic chromosome 2q region associated with tissue factor pathway inhibitor plasma levels and venous thromboembolism.
Dennis J; Truong V; Aïssi D; Medina-Rivera A; Blankenberg S; Germain M; Lemire M; Antounians L; Civelek M; Schnabel R; Wells P; Wilson MD; Morange PE; Trégouët DA; Gagnon F
J Thromb Haemost; 2016 Oct; 14(10):1960-1970. PubMed ID: 27490645
[TBL] [Abstract][Full Text] [Related]
6. [Association of single nucleotide polymorphisms of tissue factor and tissue factor pathway inhibitor with venous thromboembolism in patients with lung cancer].
Zhang XL; Zhu J; Chen WH; Zhai ZG; Zhang YH
Zhonghua Yi Xue Za Zhi; 2018 Mar; 98(12):901-906. PubMed ID: 29665662
[No Abstract] [Full Text] [Related]
7. Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients.
Königsbrügge O; Posch F; Riedl J; Reitter EM; Zielinski C; Pabinger I; Ay C
Oncologist; 2016 Feb; 21(2):252-7. PubMed ID: 26764252
[TBL] [Abstract][Full Text] [Related]
8. Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients.
Mauracher LM; Posch F; Martinod K; Grilz E; Däullary T; Hell L; Brostjan C; Zielinski C; Ay C; Wagner DD; Pabinger I; Thaler J
J Thromb Haemost; 2018 Mar; 16(3):508-518. PubMed ID: 29325226
[TBL] [Abstract][Full Text] [Related]
9. Impact of time since diagnosis and mortality rate on cancer-associated venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) cohort.
Blix K; Gran OV; Severinsen MT; Cannegieter SC; Jensvoll H; Overvad K; Hammerstrøm J; Tjønneland A; Naess IA; Braekkan SK; Rosendaal FR; Kristensen SR; Hansen JB
J Thromb Haemost; 2018 Jul; 16(7):1327-1335. PubMed ID: 29691978
[TBL] [Abstract][Full Text] [Related]
10. Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism.
Hoke M; Kyrle PA; Minar E; Bialonzcyk C; Hirschl M; Schneider B; Kollars M; Weltermann A; Eichinger S
Thromb Haemost; 2005 Oct; 94(4):787-90. PubMed ID: 16270631
[TBL] [Abstract][Full Text] [Related]
11. Red cell distribution width and other red blood cell parameters in patients with cancer: association with risk of venous thromboembolism and mortality.
Riedl J; Posch F; Königsbrügge O; Lötsch F; Reitter EM; Eigenbauer E; Marosi C; Schwarzinger I; Zielinski C; Pabinger I; Ay C
PLoS One; 2014; 9(10):e111440. PubMed ID: 25347577
[TBL] [Abstract][Full Text] [Related]
12. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.
Moik F; Chan WE; Wiedemann S; Hoeller C; Tuchmann F; Aretin MB; Fuereder T; Zöchbauer-Müller S; Preusser M; Pabinger I; Ay C
Blood; 2021 Mar; 137(12):1669-1678. PubMed ID: 33067632
[TBL] [Abstract][Full Text] [Related]
13. Genetic variation of the blood coagulation regulator tissue factor pathway inhibitor and venous thromboembolism among middle-aged and older adults: A population-based cohort study.
Manderstedt E; Lind-Halldén C; Halldén C; Elf J; Svensson PJ; Engström G; Melander O; Baras A; Lotta LA; Zöller B;
Res Pract Thromb Haemost; 2022 Oct; 6(7):e12842. PubMed ID: 36381289
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease.
Goto S; Haas S; Ageno W; Goldhaber SZ; Turpie AGG; Weitz JI; Angchaisuksiri P; Nielsen JD; Kayani G; Farjat A; Schellong S; Bounameaux H; Mantovani LG; Prandoni P; Kakkar AK;
JAMA Netw Open; 2020 Oct; 3(10):e2022886. PubMed ID: 33112399
[TBL] [Abstract][Full Text] [Related]
15. Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk.
Abu Saadeh F; Norris L; O'Toole S; Mohamed BM; Langhe R; O'Leary J; Gleeson N
Thromb Res; 2013 Nov; 132(5):627-34. PubMed ID: 24094893
[TBL] [Abstract][Full Text] [Related]
16. Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality.
Ay C; Posch F; Kaider A; Zielinski C; Pabinger I
J Thromb Haemost; 2015 Mar; 13(3):390-7. PubMed ID: 25529107
[TBL] [Abstract][Full Text] [Related]
17. ABO blood group type and risk of venous thromboembolism in patients with cancer.
Englisch C; Moik F; Nopp S; Raderer M; Pabinger I; Ay C
Blood Adv; 2022 Dec; 6(24):6274-6281. PubMed ID: 35416922
[TBL] [Abstract][Full Text] [Related]
18. Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.
Ahlbrecht J; Dickmann B; Ay C; Dunkler D; Thaler J; Schmidinger M; Quehenberger P; Haitel A; Zielinski C; Pabinger I
J Clin Oncol; 2012 Nov; 30(31):3870-5. PubMed ID: 23008313
[TBL] [Abstract][Full Text] [Related]
19. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.
Ay C; Vormittag R; Dunkler D; Simanek R; Chiriac AL; Drach J; Quehenberger P; Wagner O; Zielinski C; Pabinger I
J Clin Oncol; 2009 Sep; 27(25):4124-9. PubMed ID: 19636003
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms and plasma levels of tissue factor and tissue factor pathway inhibitor in venous thromboembolism.
Kwon A; Jo SH; Jo YA; Park JY; Kim M; Kang HJ; Kim HS; Cho HC; Lee YK
Blood Coagul Fibrinolysis; 2014 Jul; 25(5):416-21. PubMed ID: 24448154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
